We have a funded PhD studentship ‘Proteomic Signatures of Treatment Response During Pulmonary Exacerbations in Cystic Fibrosis’ available for Oct 2026 start, the application deadline is March 22nd.
We are offering a fully funded PhD studentship to investigate proteomic changes during antibiotic treatment of pulmonary exacerbations in people with cystic fibrosis (CF). This project is embedded within Trailfinder-CF and linked to the Unified clinical trial, providing a unique opportunity to work with deeply phenotyped clinical cohorts and high-quality longitudinal samples.
Pulmonary exacerbations are a major cause of morbidity in CF and are associated with accelerated lung function decline, reduced quality of life, and increased healthcare burden. Although intravenous and oral antibiotics remain the cornerstone of exacerbation management, patient responses to treatment are highly variable, and reliable biomarkers of treatment response and recovery are lacking.
This PhD project will use proteomic approaches to characterise biological responses to antibiotic therapy during pulmonary exacerbations. By analysing longitudinal samples collected before, during, and after treatment, the project aims to identify proteomic signatures associated with clinical improvement, recovery trajectories, and longer-term outcomes.
Integrating proteomic data with clinical measures will support Trailfinder-CF’s goal of enabling earlier, more precise and outcome-driven interventions in CF care.
This project is a collaboration between our lab (including co-supervisor Rosie), Paul McNamara, Jo Forthergill and Freddy Frost.
For more details please see:
https://www.findaphd.com/phds/project/proteomic-signatures-of-treatment-response-during-pulmonary-exacerbations-in-cystic-fibrosis/?p194900
Please note, unfortunately, the funding is limited to UK students only.
Comments are closed, but trackbacks and pingbacks are open.